Moderna (NASDAQ:MRNA) Given Sell (E+) Rating at Weiss Ratings

Key Points

• Moderna has been assigned a "sell (e+)" rating by Weiss Ratings, highlighting negative sentiment from analysts regarding the stock's performance.
• Despite the bearish rating, the average price target for Moderna's shares is $41.81, indicating potential upside from the current trading levels.
• In its latest earnings report, Moderna posted a loss of ($2.13) earnings per share, outperforming analyst estimates while showing a significant year-over-year revenue decline of 41.1%.

Moderna (NASDAQ:MRNA - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by stock analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other research firms also recently weighed in on MRNA. Cowen started coverage on Moderna in a research note on Sunday, July 13th. They issued a "hold" rating on the stock. Morgan Stanley restated an "equal weight" rating and set a $32.00 target price on shares of Moderna in a research note on Friday, August 1st. Evercore ISI set a $32.00 price objective on shares of Moderna in a research report on Friday, August 1st. Barclays decreased their target price on Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a research note on Monday, August 4th. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Moderna in a research note on Sunday, July 13th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fourteen have assigned a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, Moderna has an average rating of "Hold" and an average price target of $41.81.

Moderna Price Performance

NASDAQ MRNA opened at $27.92 on Wednesday. The company has a market cap of $10.90 billion, a price-to-earnings ratio of -3.71 and a beta of 2.01. Moderna has a 1 year low of $23.15 and a 1 year high of $59.73. The stock's fifty day moving average price is $25.98 and its 200 day moving average price is $27.30.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm's revenue for the quarter was down 41.1% on a year-over-year basis. During the same period in the prior year, the business posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. Research analysts expect that Moderna will post -9.61 earnings per share for the current year.

Hedge Funds Weigh In On Moderna

Several large investors have recently modified their holdings of MRNA. Czech National Bank raised its position in shares of Moderna by 5.7% in the 3rd quarter. Czech National Bank now owns 87,948 shares of the company's stock worth $2,272,000 after acquiring an additional 4,759 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Moderna by 13.8% during the third quarter. GAMMA Investing LLC now owns 10,407 shares of the company's stock valued at $269,000 after purchasing an additional 1,261 shares during the period. Corient Private Wealth LLC increased its stake in Moderna by 155.8% during the 2nd quarter. Corient Private Wealth LLC now owns 56,400 shares of the company's stock valued at $1,537,000 after purchasing an additional 34,354 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Moderna by 7.0% in the second quarter. Osaic Holdings Inc. now owns 46,709 shares of the company's stock worth $1,289,000 after purchasing an additional 3,065 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in Moderna by 600.7% in the 2nd quarter. Thrivent Financial for Lutherans now owns 92,999 shares of the company's stock worth $2,566,000 after purchasing an additional 79,726 shares in the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.